Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
- Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
- Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-09-09
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 65
- Registration Number
- NCT05533775
- Locations
- 🇧🇷
Hospital Erasto Gaertner, Curitiba, Brazil
🇧🇷GRAACC - Grupo de Apoio ao Adolescente e a Crianca com Cancer, Sao Paulo, Brazil
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations
- Conditions
- Interventions
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2022-08-19
- Target Recruit Count
- 50
- Registration Number
- NCT05507606
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
A Study to Give Treatment Inside the Eye to Treat Retinoblastoma
- Conditions
- Interventions
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 26
- Registration Number
- NCT05504291
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
Efficacy and Safety of IBI351 in Combination With Sintilimab ± Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation
- Conditions
- Interventions
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 144
- Registration Number
- NCT05504278
- Locations
- 🇨🇳
Jilin Province Cancer Hospital, Jilin, Changchun, China
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-16
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 792
- Registration Number
- NCT05502237
- Locations
- 🇦🇷
Clínica Viedma, Viedma, Argentina
🇦🇹Klinikum Klagenfurt am Woerthersee, Klagenfurt Am Woerthersee, Austria
🇺🇸Eastern CT Hematology and Oncology Associates, Norwich, Connecticut, United States
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
- Conditions
- Interventions
- Procedure: Biospecimen CollectionDrug: CarboplatinProcedure: Computed TomographyOther: Fludeoxyglucose F-18Biological: PembrolizumabDrug: Nab-paclitaxelDrug: PemetrexedProcedure: Positron Emission TomographyBiological: AtezolizumabRadiation: Radiation TherapyOther: [18-F] (fluoropropyl)-L-glutamate (FSPG) PET scanBiological: CemiplimabBiological: IpilimumabBiological: Nivolumab
- First Posted Date
- 2022-08-15
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT05501665
- Locations
- 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 390
- Registration Number
- NCT05498428
- Locations
- 🇧🇷
Associacao Hospitalar Moinhos de Vento, Porto Alegre, Brazil
🇧🇷Instituto D Or de Pesquisa e Ensino IDOR, Salvador, Brazil
🇧🇷Hospital Alemao Oswaldo Cruz, Sao Paulo, Brazil
Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer
- First Posted Date
- 2022-08-09
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- EQRx International, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT05493501
- Locations
- 🇺🇸
Northwest Medical Specialties, PLLC, Tacoma, Washington, United States
🇺🇸QCCA - Mission Blood & Cancer, Des Moines, Iowa, United States
🇺🇸Memorial Cancer Institute, Pembroke Pines, Florida, United States
A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 121
- Registration Number
- NCT05491512
- Locations
- 🇺🇸
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2022-08-08
- Target Recruit Count
- 20
- Registration Number
- NCT05491694
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.